Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Sangui Biotech International

HMSE:SBH
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SBH
HMSE
€2M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
SBH Share Price and Events
7 Day Returns
0%
HMSE:SBH
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-52%
HMSE:SBH
-13.2%
DE Biotechs
-20.9%
DE Market
SBH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sangui Biotech International (SBH) 0% -7.7% - -52% -70% -80.3%
DE Biotechs -0.7% -12.1% -22.3% -13.2% 13.2% -11.8%
DE Market -0.6% -20% -26.3% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • SBH underperformed the Biotechs industry which returned -13.2% over the past year.
  • SBH underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
SBH
Industry
5yr Volatility vs Market
Related Companies

SBH Value

 Is Sangui Biotech International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Sangui Biotech International is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sangui Biotech International has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sangui Biotech International. This is due to cash flow or dividend data being unavailable. The share price is €0.012.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sangui Biotech International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sangui Biotech International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
HMSE:SBH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $0.00
HMSE:SBH Share Price ** HMSE (2020-03-20) in EUR €0.01
HMSE:SBH Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.079 $0.01
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sangui Biotech International.

HMSE:SBH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= HMSE:SBH Share Price ÷ EPS (both in USD)

= 0.01 ÷ 0.00

-9.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sangui Biotech International is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Sangui Biotech International is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sangui Biotech International's expected growth come at a high price?
Raw Data
HMSE:SBH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.18x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sangui Biotech International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sangui Biotech International's assets?
Raw Data
HMSE:SBH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.00
HMSE:SBH Share Price * HMSE (2020-03-20) in EUR €0.01
HMSE:SBH Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.079 $0.01
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
HMSE:SBH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= HMSE:SBH Share Price ÷ Book Value per Share (both in USD)

= 0.01 ÷ 0.00

-1438.49x

* Primary Listing of Sangui Biotech International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sangui Biotech International has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at our analysis of SBH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Sangui Biotech International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sangui Biotech International has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SBH Future Performance

 How is Sangui Biotech International expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sangui Biotech International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sangui Biotech International expected to grow at an attractive rate?
  • Unable to compare Sangui Biotech International's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Sangui Biotech International's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Sangui Biotech International's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
HMSE:SBH Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
HMSE:SBH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
HMSE:SBH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 0 0
2019-09-30 0 0 0
2019-06-30 0 0 0
2019-03-31 0 0 0
2018-12-31 0 0 0
2018-09-30 0 0 0
2018-06-30 0 0 0
2018-03-31 0 0 0
2017-12-31 0 0 0
2017-09-30 0 0 0
2017-06-30 0 0 0
2017-03-31 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Sangui Biotech International is high growth as no earnings estimate data is available.
  • Unable to determine if Sangui Biotech International is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
HMSE:SBH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Sangui Biotech International Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

HMSE:SBH Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 0.00
2019-09-30 0.00
2019-06-30 0.00
2019-03-31 0.00
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sangui Biotech International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of SBH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Sangui Biotech International's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Sangui Biotech International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sangui Biotech International has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SBH Past Performance

  How has Sangui Biotech International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sangui Biotech International's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sangui Biotech International does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Sangui Biotech International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sangui Biotech International's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sangui Biotech International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sangui Biotech International Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

HMSE:SBH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.04 -0.27 0.30 0.02
2019-09-30 0.08 -0.28 0.36 0.02
2019-06-30 0.09 -0.32 0.40 0.03
2019-03-31 0.08 -0.23 0.31 0.03
2018-12-31 0.08 -0.24 0.30 0.03
2018-09-30 0.07 -0.23 0.29 0.03
2018-06-30 0.08 -0.20 0.26 0.02
2018-03-31 0.09 -0.21 0.26 0.02
2017-12-31 0.09 -0.21 0.28 0.02
2017-09-30 0.07 -0.30 0.36 0.02
2017-06-30 0.07 -0.31 0.37 0.02
2017-03-31 0.06 -0.36 0.38 0.01
2016-12-31 0.06 -0.39 0.38 0.01
2016-09-30 0.05 -0.34 0.31 0.01
2016-06-30 0.05 -0.42 0.37 0.04
2016-03-31 0.05 -0.51 0.47 0.07
2015-12-31 0.05 -0.78 0.56 0.11
2015-09-30 0.07 -0.66 0.62 0.15
2015-06-30 0.13 -0.70 0.67 0.20
2015-03-31 0.16 -0.71 0.35 0.57
2014-12-31 0.18 -1.21 0.92 0.57
2014-09-30 0.18 -1.45 0.91 0.60
2014-06-30 0.13 -1.43 0.91 0.54
2014-03-31 0.11 -2.57 1.46 0.18
2013-12-31 0.12 -2.00 0.89 0.15
2013-09-30 0.13 -2.09 1.27 0.09
2013-06-30 0.11 -2.10 1.27 0.07

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sangui Biotech International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Sangui Biotech International has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sangui Biotech International improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Sangui Biotech International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sangui Biotech International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SBH Health

 How is Sangui Biotech International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sangui Biotech International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sangui Biotech International's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Sangui Biotech International has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sangui Biotech International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sangui Biotech International has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sangui Biotech International Company Filings, last reported 3 months ago.

HMSE:SBH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -0.65 0.54 0.02
2019-09-30 -0.59 0.48 0.02
2019-06-30 -0.59 0.48 0.03
2019-03-31 -0.48 0.38 0.02
2018-12-31 -0.40 0.31 0.04
2018-09-30 -0.43 0.38 0.05
2018-06-30 -0.35 0.24 0.02
2018-03-31 -0.40 0.26 0.02
2017-12-31 -0.32 0.19 0.02
2017-09-30 -0.29 0.16 0.05
2017-06-30 -0.26 0.15 0.06
2017-03-31 -0.29 0.14 0.05
2016-12-31 -0.22 0.15 0.12
2016-09-30 -0.21 0.15 0.10
2016-06-30 -0.25 0.15 0.07
2016-03-31 -0.22 0.15 0.05
2015-12-31 -0.33 0.15 0.09
2015-09-30 -0.45 0.20 0.01
2015-06-30 -0.34 0.20 0.02
2015-03-31 -0.20 0.11 0.11
2014-12-31 -0.06 0.00 0.09
2014-09-30 -0.07 0.00 0.06
2014-06-30 0.01 0.00 0.10
2014-03-31 -0.11 0.02 0.04
2013-12-31 0.38 0.02 0.14
2013-09-30 0.51 0.02 0.23
2013-06-30 0.30 0.02 0.05
  • Sangui Biotech International has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Sangui Biotech International's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sangui Biotech International has less than a year of cash runway based on current free cash flow.
  • Sangui Biotech International has less than a year of cash runway if free cash flow continues to reduce at historical rates of -23.3% each year.
X
Financial health checks
We assess Sangui Biotech International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sangui Biotech International has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SBH Dividends

 What is Sangui Biotech International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sangui Biotech International dividends.
If you bought €2,000 of Sangui Biotech International shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sangui Biotech International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sangui Biotech International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
HMSE:SBH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sangui Biotech International has not reported any payouts.
  • Unable to verify if Sangui Biotech International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sangui Biotech International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sangui Biotech International has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sangui Biotech International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sangui Biotech International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sangui Biotech International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SBH Management

 What is the CEO of Sangui Biotech International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thomas Striepe
COMPENSATION $68,454
AGE 57
TENURE AS CEO 12 years
CEO Bio

Mr. Thomas Striepe has been the Chief Executive Officer of Sangui Biotech International Inc., since April 8, 2008 and serves as its Chief Financial Officer. Mr. Striepe serves as the Vice President of Accounting and Controlling at Dr. Ludz GmbH, Hamburg, Germany, a financial services company. He served as Member of the Management Board at Feedback AG since 2005 until December 31, 2015. He is responsible for various group financial statements and the development and building of reporting and planning systems. He served as Member of the Management Board of Dr. Ludz Verm gensberatungs -und Vermittlungsgesellschaft mbH from 2004. He held management positions in the accounting departments of several German and international corporations. He has been a Non-Executive Director of Sangui Biotech International Inc., since February 7, 2005. He served as President at Sangui Biotech International, Inc. Mr. Striepe obtained MBA from Hamburg University. From 1982 to 1988, Mr. Striepe studied Business Management, majoring in Accounting and Taxes in Hamburg.

CEO Compensation
  • Thomas's compensation has increased whilst company is loss making.
  • Thomas's remuneration is lower than average for companies of similar size in Germany.
Management Team

Thomas Striepe

TITLE
CEO, CFO & Executive Director
COMPENSATION
$68K
AGE
57
TENURE
12 yrs
Board of Directors

Thomas Striepe

TITLE
CEO, CFO & Executive Director
COMPENSATION
$68K
AGE
57
TENURE
15.2 yrs

Hubertus Schmelz

TITLE
Non-Executive Director
AGE
64
TENURE
11.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Sangui Biotech International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sangui Biotech International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SBH News

Simply Wall St News

SBH Company Info

Description

Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through Internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.

Details
Name: Sangui Biotech International, Inc.
SBH
Exchange: HMSE
Founded: 1995
€2,432,758
202,729,842
Website: http://www.sanguibiotech.com
Address: Sangui Biotech International, Inc.
Neuer Wall 54,
Hamburg,
20354,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
HMSE SBH Common Stock Hamburg Stock Exchange DE EUR 18. Mar 1999
OTCPK SGBI Common Stock Pink Sheets LLC US USD 18. Mar 1999
Number of employees
Current staff
Staff numbers
1
Sangui Biotech International employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 21:54
End of day share price update: 2020/03/20 00:00
Last earnings filing: 2020/02/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.